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Abstract
Purpose of Review—Chronic Kidney Disease (CKD) affects nearly 10% of the population. The 
incidence of fractures in population studies demonstrate an increase with worsening stages of 
kidney disease suggesting specific CKD related causes of fracture.
Recent Findings—The increase in fractures with CKD most likely represents disordered bone 
quality due to the abnormal bone remodeling from renal osteodystrophy. There is also an increase 
in fractures with age in patients with CKD, suggesting that patients with CKD also have many 
fracture risk factors common to patients without known CKD. Osteoporosis is defined by the 
National Institutes of Health as “A skeletal disorder characterized by compromised bone strength 
predisposing to an increased risk of fracture. Bone strength reflects the integration of two main 
features: bone quantity and bone quality”.
Summary—Thus, CKD related fractures can be considered a type of osteoporosis- where the 
bone quality is additionally impaired above that of age/hormonal related osteoporosis. Perhaps 
using the term CKD induced osteoporosis, similar to steroid induced osteoporosis, will allow 
patients with CKD to be studied in trials investigating therapeutic agents. In this series we will 
examine how CKD induced osteoporosis may be diagnosed and treated.
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Introduction
Chronic Kidney Disease (CKD) affects between 8 and 10% of the world population[1] with 
an increasing prevalence due to the rise in diabetes, the leading cause of kidney disease. 
Bone disease is a major complication of CKD and is one manifestation of CKD-Mineral 
Bone Disorder (CKD-MBD) (Table 1). Renal osteodystrophy is an alteration of bone 
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morphology in patients with CKD and is one measure of the skeletal component of the 
systemic disorder of CKD-MBD that is quantifiable by histomorphometry assessed on bone 
biopsy[2]. The pathogenesis of renal osteodystrophy is complex and, as described elsewhere 
in this series by Susan Ott, the nomenclature has evolved as we slowly unravel the complex 
physiology. There is also an inverse relationship between arterial calcification and bone 
calcification (density or area) in CKD[3–5] implying system disordered metabolism and the 
uremic milieu may alter bone. Traditionally, the primary focus on bone health has been to 
control parathyroid hormone (PTH) with calcitriol or other vitamin D analogs and more 
recently with calcimimetics. Clearly secondary and tertiary hyperparathyroidism has a major 
role in stimulating bone remodeling in CKD. However, studies have demonstrated the 
incidence of age adjusted hip fracture has actually increased over the past decades despite an 
intensive focus on treatments for renal osteodystrophy such as PTH and phosphate lowering 
therapies[6,7]. Thus, there is more to abnormal bone in patients with CKD than just PTH.
Fractures are very common in CKD, and the incidence increases with progressive CKD 
(Figure 1). The progressive rise in incidence of fracture with more advanced CKD suggests 
risk factors caused by CKD, further supported by a 2 to 3 fold increased fracture risk in 
children with CKD[8]. However, the progressive rise in incidence with age at all stages of 
CKD suggests that other factors, perhaps those common to advanced aging, also play a role. 
The average age of patients starting dialysis has progressively risen over time, and thus 
many patients will already have risk factors for fracture prior to developing kidney disease. 
Known risk factors for fracture in the general population include family history of fracture, 
previous fracture, ethnicity and bone structure, peak bone mass, hormone deficiency, 
smoking, alcohol use, and falls. These risk factors are clearly independent of the presence or 
absence of CKD yet may be exacerbated by CKD. For example, hormone deficiency is 
nearly universal in both male and female patients with CKD[9,10]. Falls are more common 
in CKD due to peripheral neuropathy of diabetes and uremia[11] and a high prevalence of 
sarcopenia[12] and have been associated with fracture in patients with CKD.
Operationally, the World Health Organization considers low bone mineral density (BMD) 
assessed by dual X-ray absorptiometry (DXA) to be synonymous with osteoporosis. 
However, the improvement in BMD in response to treatments is small compared to fracture 
risk reduction in therapeutic trials, indicating there is more to bone than bone mineral 
density[13]. In 2000, the NIH defined osteoporosis as “A skeletal disorder characterized by 
compromised bone strength predisposing to an increased risk of fracture. Bone strength 
reflects the integration of two main features: bone quantity and bone quality”[14]. Thus bone 
quantity (assessed by DXA to give 2-dimensional areal bone density or with quantified 
computed tomography (CT) for area) is only one component. Bone quality is a second major 
component and includes bone remodeling abnormalities, collagen cross linking and 
mineralization properties. Remodeling abnormalities are generally evaluated with bone 
biopsy and dynamic histomorphometry (tetracycline labeling) and such abnormalities are 
nearly universally abnormal in patients with CKD[15]. Thus, renal osteodystrophy is one 
component of abnormal bone quality, not the only cause of fractures. Treatments only 
focused on the abnormal bone remodeling of CKD are thus not likely to be efficacious in 
preventing fractures due to the many other risk factors for low bone mass and other factors 
adversely affecting bone quality.
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The organization Kidney Disease Improving Global Outcomes (KDIGO) recommended 
using the term renal osteodystrophy to define abnormalities in turnover, mineralization, and 
volume assessed by bone biopsy as “Renal osteodystrophy”[2]. But in the definition of 
CKD-MBD (Table 1), strength (or increased fragility) was also a component of abnormal 
bone indicating that fractures, regardless of the underlying histology, also are a 
manifestation of CKD-MBD. Indeed volume is a key characteristic of both underlying 
abnormal bone histology (a.k.a. renal osteodystrophy) and a major component contributing 
to fragility (low impact) fractures. Thus, the assessment of bone volume by DXA or CT 
based methods may be helpful in management of patients with high risk of fracture and may 
provide additive information to that obtained with bone biopsy.
Unfortunately, data supporting that BMD testing is relevant in CKD has lagged behind that 
generated in the general population. In the 2003 Kidney Disease Outcomes Quality Initiative 
(K/DOQI) guidelines, BMD testing was only recommended in post-transplant patients as 
there were no studies in patients with CKD demonstrating that a low BMD by DXA 
predicted subsequent fracture. In other words, its utility as a screening tool to identify those 
patients at risk was not yet proven.[16]. There was also concern that DXA may be artificially 
elevated in the setting of arterial calcification, especially at the lumbar spine[16]. In the 2009 
KDIGO CKD-MBD guidelines there were studies demonstrating that low BMD predicted 
fractures in patients with all stages of CKD[17–21]. However, the consensus was that the 
risk of treating patients with the commonly used class of drugs, bisphosphonates, was high 
and the benefit uncertain despite secondary analyses of common anti-osteoporosis 
treatments in post-menopausal women. Unfortunately, these secondary analyses included 
generally normal creatinine and normal PTH levels and it was felt the results were not 
generalizable to more advanced CKD (See article by Paul Miller). Therefore the guideline 
did not recommend screening because there was no treatment[22]. In 2016 KDIGO 
guideline update (currently out for public comment www.kdigo.org), BMD is now 
recommended “if the results will change clinical management”. The committee felt that 
although treatment options remain ill-defined and under-studied, in some patients, the 
treatment outweighs risk and clinicians must individualize treatments.
In the general population, clinical risk factors have been combined into a fracture prediction 
algorithm called Fracture Risk Assessment Tool or FRAX®, developed by the World Health 
Organization[23]. The goal of FRAX is to evaluate fracture risk of patients on an individual 
basis. The various FRAX tools have been refined in different countries to take into account 
the genetics of bone fracture. There are many risk factors for fractures utilized in FRAX 
models, including age, sex, body mass index, family history, alcohol use, smoking, 
glucocorticoids and rheumatoid arthritis. There is also an option to say ‘yes’ or ‘no’ to a 
question asking for the presence of secondary osteoporosis (including diabetes, osteogenesis 
imperfecta, long standing hyperthyroidism, hypogonadism, premature menopause, chronic 
malnutrition, or malabsorption and chronic liver disease). Although CKD is not on this list, 
it probably should be given the obvious increase incidence of fracture with progressive CKD 
shown in Figure 1. Studies have demonstrated that the use of FRAX discriminates those with 
and without fracture in both patients with advanced CKD[24] and transplant recipients[25]. 
The addition of BMD to the FRAX score improves the prediction of fracture risk.
Moe Page 3
Curr Osteoporos Rep. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Thus, assessments of bone health in the general population with tools such as BMD and 
FRAX risk assessment appear to be relevant in patients with CKD. The presence of CKD 
likely increases the fracture risk above that assessed by these tools and should be regarded as 
an independent risk factor for fracture, similar to how CKD is now considered an 
independent risk factor for cardiovascular disease. Fractures are one of many ‘premature 
aging’ consequences observed in patients with CKD. Mortality doubles in patients on 
dialysis who sustain a major fracture that requires hospitalization[26,27] and thus fractures 
have major consequences. Unfortunately, patients with CKD are uniformly excluded from 
clinical trials evaluating pharmacotherapies. While post hoc analyses have identified low 
GFR in many patients enrolled in these trials as discussed in another article in this series by 
Paul Miller, the presence of a single measure of low GFR does not define CKD[1]. The first 
step is to consider Renal Osteodystrophy a form of osteoporosis, or at least a major risk 
factor. Perhaps we should coin a new term- “CKD induced osteoporosis” as a parallel term 
to corticosteroid induced osteoporosis. Studies must examine the utility of currently 
available and new therapies specifically in patients with CKD. It is likely that concomitant 
therapy to treat the abnormal bone remodeling through control of PTH will also be needed, 
but only prospective studies can determine the optimal treatment. In this series, we will 
focus on renal osteodystrophy and the similarities and differences with other forms of 
osteoporosis. Our hope is that CKD becomes a recognized major risk factor for fracture.
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Figure 1. Hip Fracture Incidence Increases with Progressive CKD
As patients age in the general population there is an increased incidence of hip fracture. This 
incidence increases with progression of CKD. Data from Alem et al for dialysis patients and 
the general population from Olmstead Minnesota[28], Naylor et al for CKD stages 3–4[29] 
courtesy of the Canadian Institute for Clinical Evaluative Sciences (ICES). Pt-yrs = patient 
years. From: Moe SM, Nickolas TL. Fractures in patients with CKD: Time for Action. Clin 
J Am Soc Nephrol. 2016 Nov 7;11(11):1929–1931. Epub 2016 Oct 24. Used with 
permission from the American Society of Nephrology.
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Table 1
Kidney Disease Improving Global Outcomes (KDIGO) classification of CKD-MBD and Renal 
Osteodystrophy
Definition of CKD-MBD
A systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following:
• Abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism
• Abnormalities in bone turnover, mineralization, volume, linear growth, or strength
• Vascular or other soft tissue calcification
Definition of Renal Osteodystrophy
• Renal osteodystrophy is an alteration of bone morphology in patients with CKD.
• It is one measure of the skeletal component of the systemic disorder of CKD-MBD that is quantifiable by histomorphometry of 
bone biopsy.
From: Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney 
Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69(11):1945–53. Used with permission from Elsevier.
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